Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

f any intensity that occurred at a higher rate than placebo were rash (16.9 percent vs. 9.3 percent) and nausea (13.9 percent vs. 11.1 percent). The most common treatment-emergent adverse reactions (Grade 2-4) that occurred in greater than or equal to two percent of patients receiving an INTELENCE-containing regimen were diarrhea, nausea, abdominal pain, vomiting, fatigue, peripheral neuropathy, headache, rash, and hypertension.

Additional Important Safety Information

INTELENCE does not cure HIV infection or AIDS, and does not prevent passing HIV to others.

-- Severe and potentially life-threatening skin reactions, including

Stevens-Johnson Syndrome, hypersensitivity reaction, and erythema

multiforme, have occurred (< 0.1 percent) in patients taking INTELENCE.

Treatment with INTELENCE should be discontinued and appropriate therapy

initiated if severe rash develops.

-- In general, in clinical trials, rash was mild to moderate, occurred

primarily in the second week of therapy, and was infrequent after Week

4. Rash generally resolved within 1-2 weeks on continued therapy.

Discontinuation rate due to rash was two percent.

-- Redistribution and/or accumulation of body fat have been observed in

patients receiving antiretroviral (ARV) therapy. The causal

relationship, mechanism, and long-term consequences of these events

have not been established.

-- Immune reconstitution syndrome has been reported in patients treated

with ARV therapy, including INTELENCE.

-- INTELENCE should be used with caution in patients with severe hepatic

impairment (Child-Pugh class C) as pharmacokinetics of INTELENCE have

not been evaluated in these patients.

Drug Interactions

-- INTELENCE should not be co-administered with the following ARVs:

tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavi
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 /PRNewswire/ ... company advancing patient care in critical areas, announced the ... of common stock, and warrants to purchase up to ... offering price of $4.00 per share and $.01 per ... of $5.00, are exercisable immediately, and expire 5 years ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ... forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Md., Oct. 12 Sequella, Inc., a clinical-stage ... treat life-threatening infectious diseases, today announced that it ... (SBIR) grant from the National Institutes of Health ... (NIAID) for the development of SQ641, Sequella,s lead ...
... Calif., Oct. 12 Raptor Pharmaceutical Corp. ("Raptor" or ... from the completed treatment phase of its open-label Phase ... in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive ... 5% of the U.S. population. At the completion of ...
... , ... singer, Cynthia Basinet petitions the United Nations Sixty-fourth General Assembly Fourth Committee on behalf ... ... and singer, Cynthia Basinet petitions the United Nations Sixty-fourth General Assembly Fourth Committee on ...
Cached Biology Technology:Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 2Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 5Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 6Actress and Singer, Cynthia Basinet Petitions United Nations 2
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... entertainer and security consultant, Apollo Robbins for ... smart wallet.  Apollo Robbins ... 7 th , 2015, demonstrating some of his famous ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Vertebral fractures are a common cause of ... powerful predictors of future spine and hip fractures. ... simply fail to recognize vertebral fractures in their ... intervention is often not initiated. The Vertebral ...
... CHICAGO, IL (May 8, 2011) Research being ... individuals for hepatitis C based on age instead of ... well as prevent liver disease. Additionally, the rate of ... disease and type 2 diabetes is relatively low, and ...
... the Faculty of Medicine & Dentistry at the University ... kill neurons. This finding is significant because a specific ... medical community as a potential treatment for MS and ... post-doctoral fellow, Yohannes Haile, both from the Division of ...
Cached Biology News:New IOF teaching tool helps health professionals identify vertebral fractures 2Strides in identifying and improving screening practices and treatment for liver diseases 2Discovery demonstrates potential MS therapy could kill brain cells 2
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
...
...
... cabinets Heraeus HERAsafe KS convince with an optimum ... new frameless slanted window does not obscure the ... window design makes it easy to work in ... a height of more than 250 mm ensures ...
Biology Products: